TNF and Takayasu arteritis: TNF inhibition (typically infliximab) has circumstantial evidence suggesting efficacy in open label use for large vessel vasculitis secondary to refractory Takayasu’s arteritis, relapsing polychondritis, Behçet’s disease (also including adalimumab), and relapsing polychondritis.